As expected, a breast cancer cell line derived from an individual expressing this NQO1 variant (MDA-MB-231) was largely resistant to CBK77 with an IC50 of >50 μM, which was very similar to the sensitivity of the cell line to the poorly active CBK07 analogue (Fig. 8A). This evidence concerns the gene NQO1 and breast carcinoma.